Last updated on May 2020

A Study to Evaluate Safety Efficacy Pharmacokinetics and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Central Precocious Puberty | Testotoxicosis | Precocious Puberty
  • Age: Between 2 - 11 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Children with CPP who are nave to treatment with a gonadotropin-releasing hormone agonist (GnRHa) (females 2 - 8 years of age, or males 2 - 9 years of age) or who have been on standard GnRHa therapy for at least 6 months (females 2 - 10 years of age, or males 2 - 11 years of age).
  • No history of clinically significant medical conditions or any other reason that the investigator determines would make the participant an unsuitable candidate to receive study drug.

Exclusion Criteria:

  • NA

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.